Ever since Amazon launched its digital pharmacy late last year, industry rivals have been worried the tech giant would steal the show. Rather than waiting to find out, they’re all scrambling to secure their spot on the stage.
Some, like Nurx and Folx, are zeroing in on underserved or specific populations, hoping to build a loyal, lifetime patient pool. Others, such as Hims, Ro, and GoodRx, are going broad: adding new telemedicine services, offering steep discounts and subscription perks, and in some cases, pitching themselves as a trustworthy, more bespoke alternative to Amazon.
For these companies, “it’s a race to be the first place patients go when they need anything in health care,” said Andrew Matzkin, a partner at the consulting firm Health Advances.
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect